Detailed Mechanism Funding and Narrative

Years of mechanism: 2018 2019 2020

Details for Mechanism ID: 18676
Country/Region: Nigeria
Year: 2018
Main Partner: Caritas Internationalis
Main Partner Program: Catholic Caritas Foundation of Nigeria (CCFN)
Organizational Type: Implementing Agency
Funding Agency: HHS/CDC
Total Funding: $5,806,210 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $757,344
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $199,711
Care: Pediatric Care and Support (PDCS) $439,366
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $751,765
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,061,775
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $2,476,421
Treatment: Pediatric Treatment (PDTX) $119,828
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2019 6
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2019 42
GEND_GBV <10, Male, Physical and/or Emotional Violence 2019 9
GEND_GBV <10, Male, Sexual Violence (Post-Rape Care) 2019 9
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2019 8
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2019 68
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2019 22
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2019 16
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2019 45
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 42
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2019 16
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2019 14
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2019 83
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 77
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2019 65
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2019 8
GEND_GBV 25-29, Female, Physical and/or Emotional Violence 2019 175
GEND_GBV 25-29, Female, Sexual Violence (Post-Rape Care) 2019 58
GEND_GBV 25-29, Male, Physical and/or Emotional Violence 2019 270
GEND_GBV 25-29, Male, Sexual Violence (Post-Rape Care) 2019 26
GEND_GBV 30-34, Female, Physical and/or Emotional Violence 2019 69
GEND_GBV 30-34, Female, Sexual Violence (Post-Rape Care) 2019 22
GEND_GBV 30-34, Male, Physical and/or Emotional Violence 2019 106
GEND_GBV 30-34, Male, Sexual Violence (Post-Rape Care) 2019 8
GEND_GBV 35-39, Female, Physical and/or Emotional Violence 2019 51
GEND_GBV 35-39, Female, Sexual Violence (Post-Rape Care) 2019 18
GEND_GBV 35-39, Male, Physical and/or Emotional Violence 2019 78
GEND_GBV 35-39, Male, Sexual Violence (Post-Rape Care) 2019 7
GEND_GBV 40-49, Female, Physical and/or Emotional Violence 2019 51
GEND_GBV 40-49, Female, Sexual Violence (Post-Rape Care) 2019 18
GEND_GBV 40-49, Male, Physical and/or Emotional Violence 2019 78
GEND_GBV 40-49, Male, Sexual Violence (Post-Rape Care) 2019 7
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2019 3
GEND_GBV 50+, Female, Sexual Violence (Post-Rape Care) 2019 15
GEND_GBV 50+, Male, Physical and/or Emotional Violence 2019 6
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 415
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2019 1,157
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 465
GEND_GBV Number of people receiving post-GBV care 2019 1,620
HTS_SELF 2019 294
HTS_SELF 20-24, Female, Directly-Assisted 2019 7
HTS_SELF 20-24, Female, Unassisted 2019 7
HTS_SELF 20-24, Male, Directly-Assisted 2019 1
HTS_SELF 20-24, Male, Unassisted 2019 1
HTS_SELF 25-29, Female, Directly-Assisted 2019 18
HTS_SELF 25-29, Female, Unassisted 2019 18
HTS_SELF 25-29, Male, Directly-Assisted 2019 10
HTS_SELF 25-29, Male, Unassisted 2019 10
HTS_SELF 30-34, Female, Directly-Assisted 2019 18
HTS_SELF 30-34, Female, Unassisted 2019 18
HTS_SELF 30-34, Male, Directly-Assisted 2019 4
HTS_SELF 30-34, Male, Unassisted 2019 4
HTS_SELF 35-39, Female, Directly-Assisted 2019 17
HTS_SELF 35-39, Female, Unassisted 2019 17
HTS_SELF 35-39, Male, Directly-Assisted 2019 8
HTS_SELF 35-39, Male, Unassisted 2019 8
HTS_SELF 40-49, Female, Directly-Assisted 2019 20
HTS_SELF 40-49, Female, Unassisted 2019 20
HTS_SELF 40-49, Male, Directly-Assisted 2019 12
HTS_SELF 40-49, Male, Unassisted 2019 12
HTS_SELF 50+, Female, Directly-Assisted 2019 14
HTS_SELF 50+, Female, Unassisted 2019 14
HTS_SELF 50+, Male, Directly-Assisted 2019 9
HTS_SELF 50+, Male, Unassisted 2019 9
HTS_SELF Directly-Assisted 2019 147
HTS_SELF Unassisted 2019 147
HTS_SELF Unassisted - Other 2019 15
HTS_SELF Unassisted - Self 2019 28
HTS_SELF Unassisted - Sex Partner 2019 28
HTS_TST 25-29, Female, Negative 2019 56
HTS_TST 25-29, Female, Negative 2019 821
HTS_TST 25-29, Female, Negative 2019 20,126
HTS_TST 25-29, Female, Negative 2019 59,691
HTS_TST 25-29, Female, Negative 2019 182
HTS_TST 25-29, Female, Negative 2019 6,412
HTS_TST 25-29, Male, Negative 2019 47
HTS_TST 25-29, Male, Negative 2019 655
HTS_TST 25-29, Male, Negative 2019 9,111
HTS_TST 25-29, Male, Negative 2019 103
HTS_TST 25-29, Male, Negative 2019 4,509
HTS_TST 30-34, Female, Negative 2019 56
HTS_TST 30-34, Female, Negative 2019 621
HTS_TST 30-34, Female, Negative 2019 10,980
HTS_TST 30-34, Female, Negative 2019 39,665
HTS_TST 30-34, Female, Negative 2019 167
HTS_TST 30-34, Female, Negative 2019 4,280
HTS_TST 30-34, Male, Negative 2019 144
HTS_TST 30-34, Male, Negative 2019 406
HTS_TST 30-34, Male, Negative 2019 7,409
HTS_TST 30-34, Male, Negative 2019 103
HTS_TST 30-34, Male, Negative 2019 3,168
HTS_TST 35-39, Female, Negative 2019 93
HTS_TST 35-39, Female, Negative 2019 571
HTS_TST 35-39, Female, Negative 2019 8,754
HTS_TST 35-39, Female, Negative 2019 14,966
HTS_TST 35-39, Female, Negative 2019 105
HTS_TST 35-39, Female, Negative 2019 3,029
HTS_TST 35-39, Male, Negative 2019 177
HTS_TST 35-39, Male, Negative 2019 444
HTS_TST 35-39, Male, Negative 2019 5,354
HTS_TST 35-39, Male, Negative 2019 138
HTS_TST 35-39, Male, Negative 2019 2,931
HTS_TST 40-49, Female, Negative 2019 64
HTS_TST 40-49, Female, Negative 2019 646
HTS_TST 40-49, Female, Negative 2019 7,315
HTS_TST 40-49, Female, Negative 2019 3,244
HTS_TST 40-49, Female, Negative 2019 168
HTS_TST 40-49, Female, Negative 2019 2,058
HTS_TST 40-49, Male, Negative 2019 98
HTS_TST 40-49, Male, Negative 2019 499
HTS_TST 40-49, Male, Negative 2019 4,494
HTS_TST 40-49, Male, Negative 2019 193
HTS_TST 40-49, Male, Negative 2019 2,822
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 349,820
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2019 21
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 5,458
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 30,562
HTS_TST Service Delivery Point (Facility) ANC: 50+, Negative 2019 25
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 101
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 51
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 170
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 212
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 101
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 205
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 1,488
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 328
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 335
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 287
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 165
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 813
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 272
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 544
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 445
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 7,315
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 3,944
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 4,857
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 2,960
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 1,719
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 7,914
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 3,611
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 610
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 597
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 909
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 168
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 143
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 110
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 175
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 136
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 151
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 192
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 186
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2019 2,306
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2019 2,743
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2019 2,871
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 4,558
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 2,700
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 7,323
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 4,866
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 4,762
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 3,100
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2019 20
HTS_TST_POS 25-29, Female, Positive 2019 82
HTS_TST_POS 25-29, Female, Positive 2019 57
HTS_TST_POS 25-29, Female, Positive 2019 513
HTS_TST_POS 25-29, Female, Positive 2019 767
HTS_TST_POS 25-29, Female, Positive 2019 13
HTS_TST_POS 25-29, Female, Positive 2019 631
HTS_TST_POS 25-29, Male, Positive 2019 43
HTS_TST_POS 25-29, Male, Positive 2019 281
HTS_TST_POS 25-29, Male, Positive 2019 13
HTS_TST_POS 25-29, Male, Positive 2019 114
HTS_TST_POS 30-34, Female, Positive 2019 49
HTS_TST_POS 30-34, Female, Positive 2019 37
HTS_TST_POS 30-34, Female, Positive 2019 513
HTS_TST_POS 30-34, Female, Positive 2019 84
HTS_TST_POS 30-34, Female, Positive 2019 19
HTS_TST_POS 30-34, Female, Positive 2019 391
HTS_TST_POS 30-34, Male, Positive 2019 31
HTS_TST_POS 30-34, Male, Positive 2019 140
HTS_TST_POS 30-34, Male, Positive 2019 18
HTS_TST_POS 30-34, Male, Positive 2019 146
HTS_TST_POS 35-39, Female, Positive 2019 82
HTS_TST_POS 35-39, Female, Positive 2019 78
HTS_TST_POS 35-39, Female, Positive 2019 386
HTS_TST_POS 35-39, Female, Positive 2019 81
HTS_TST_POS 35-39, Female, Positive 2019 16
HTS_TST_POS 35-39, Female, Positive 2019 350
HTS_TST_POS 35-39, Male, Positive 2019 59
HTS_TST_POS 35-39, Male, Positive 2019 36
HTS_TST_POS 35-39, Male, Positive 2019 282
HTS_TST_POS 35-39, Male, Positive 2019 19
HTS_TST_POS 35-39, Male, Positive 2019 235
HTS_TST_POS 40-49, Female, Positive 2019 49
HTS_TST_POS 40-49, Female, Positive 2019 37
HTS_TST_POS 40-49, Female, Positive 2019 642
HTS_TST_POS 40-49, Female, Positive 2019 14
HTS_TST_POS 40-49, Female, Positive 2019 473
HTS_TST_POS 40-49, Male, Positive 2019 36
HTS_TST_POS 40-49, Male, Positive 2019 66
HTS_TST_POS 40-49, Male, Positive 2019 356
HTS_TST_POS 40-49, Male, Positive 2019 16
HTS_TST_POS 40-49, Male, Positive 2019 413
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 14
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 294
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 46
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 23
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 41
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive 2019 11
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 38
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 14
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2019 35
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2019 25
HTS_TST_POS Service Delivery Point (Facility) Other PITC: <1, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 122
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2019 52
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 37
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 42
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 39
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 402
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 112
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 18
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 14
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 18
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Female, Positive 2019 9
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 23
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 15
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) VCT: 1-9, Positive 2019 79
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Female, Positive 2019 104
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Male, Positive 2019 66
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 91
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 45
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 356
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 99
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2019 238
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 179
PMTCT_ART Already on ART at beginning of current pregnancy 2019 1,916
PMTCT_ART New on ART 2019 1,145
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 3,061
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 159,192
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 2,319
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 580
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 2,899
PMTCT_EID Sum of Infant Age disaggregates 2019 2,899
PMTCT_STAT 25-29, Female 2019 61,417
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 759
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 60,165
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 491
PMTCT_STAT 30-34, Female 2019 41,748
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 511
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 40,900
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 328
PMTCT_STAT 35-39, Female 2019 16,701
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 201
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 16,363
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 138
PMTCT_STAT 40-49, Female 2019 3,535
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 32
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 3,469
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 13
PMTCT_STAT By Age (Numerator): 10-14 2019 287
PMTCT_STAT By Age (Numerator): 15-19 2019 4,782
PMTCT_STAT By Age (Numerator): 20-24 2019 30,330
PMTCT_STAT By Age (Numerator): 50+ 2019 757
PMTCT_STAT By Number of known positives: 15-19 2019 68
PMTCT_STAT By Number of known positives: 20-24 2019 363
PMTCT_STAT By Number of known positives: 50+ 2019 1
PMTCT_STAT By Number of new negative: 10-14 2019 277
PMTCT_STAT By Number of new negative: 15-19 2019 4,686
PMTCT_STAT By Number of new negative: 20-24 2019 29,731
PMTCT_STAT By Number of new negative: 50+ 2019 744
PMTCT_STAT By Number of new positives: 15-19 2019 42
PMTCT_STAT By Number of new positives: 20-24 2019 241
PMTCT_STAT Number of new ANC and L&D clients 2019 167,971
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 159,192
PMTCT_STAT_den 25-29, Female 2019 64,644
PMTCT_STAT_den 30-34, Female 2019 43,947
PMTCT_STAT_den 35-39, Female 2019 17,582
PMTCT_STAT_den 40-49, Female 2019 3,724
PMTCT_STAT_den By Age (Denominator): <15-19 2019 5,037
PMTCT_STAT_den By Age (Denominator): 10-14 2019 301
PMTCT_STAT_den By Age (Denominator): 20-24 2019 31,936
PMTCT_STAT_den By Age (Denominator): 50+ 2019 800
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 5
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 297
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 6
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 292
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 596
TB_PREV By Age/Sex (Numerator): <15, Female 2019 359
TB_PREV By Age/Sex (Numerator): <15, Male 2019 253
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 23,646
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 11,591
TB_PREV IPT, Life-long ART, Already, Positive 2019 34,050
TB_PREV IPT, Life-long ART, New, Positive 2019 1,799
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 35,844
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 39,825
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 249
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 198
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 26,004
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 13,378
TB_PREV_den IPT, Life-long ART, Already, Positive 2019 37,836
TB_PREV_den IPT, Life-long ART, New, Positive 2019 1,998
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 44
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 1,155
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 59
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 1,570
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 2,823
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 2,823
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 44
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 1,155
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 59
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 1,570
TX_CURR 25-29, Female, Positive 2019 5,375
TX_CURR 25-29, Male, Positive 2019 1,567
TX_CURR 30-34, Female, Positive 2019 8,343
TX_CURR 30-34, Male, Positive 2019 1,682
TX_CURR 35-39, Female, Positive 2019 8,668
TX_CURR 35-39, Male, Positive 2019 2,379
TX_CURR 40-49, Female, Positive 2019 10,887
TX_CURR 40-49, Male, Positive 2019 5,062
TX_CURR Age/Sex: <1 2019 28
TX_CURR Age/Sex: <1-9 2019 2,072
TX_CURR Age/Sex: 10-14 Female 2019 560
TX_CURR Age/Sex: 10-14 Male 2019 600
TX_CURR Age/Sex: 15-19 Female 2019 464
TX_CURR Age/Sex: 15-19 Male 2019 335
TX_CURR Age/Sex: 20-24 Female 2019 1,459
TX_CURR Age/Sex: 20-24 Male 2019 507
TX_CURR Age/Sex: 50+ Female 2019 6,535
TX_CURR Age/Sex: 50+ Male 2019 5,150
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 61,621
TX_CURR Sum of age/sex disaggregates 2019 799
TX_NEW 25-29, Female, Positive 2019 1,234
TX_NEW 25-29, Male, Positive 2019 562
TX_NEW 30-34, Female, Positive 2019 799
TX_NEW 30-34, Male, Positive 2019 356
TX_NEW 35-39, Female, Positive 2019 976
TX_NEW 35-39, Male, Positive 2019 447
TX_NEW 40-49, Female, Positive 2019 1,514
TX_NEW 40-49, Male, Positive 2019 694
TX_NEW Breastfeeding status 2019 45
TX_NEW By Age/Sex: <1 2019 55
TX_NEW By Age/Sex: 1-9 2019 369
TX_NEW By Age/Sex: 10-14 Female 2019 80
TX_NEW By Age/Sex: 10-14 Male 2019 73
TX_NEW By Age/Sex: 15-19 Female 2019 140
TX_NEW By Age/Sex: 15-19 Male 2019 74
TX_NEW By Age/Sex: 20-24 Female 2019 529
TX_NEW By Age/Sex: 20-24 Male 2019 178
TX_NEW By Age/Sex: 50+ Female 2019 887
TX_NEW By Age/Sex: 50+ Male 2019 614
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 9,522
TX_NEW Pregnancy status 2019 644
TX_NEW Sum of Age/Sex disaggregates 2019 2,575
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 60,445
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 1,448
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 1,392
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 40,529
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 198
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 16,835
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 44
TX_PVLS_den Denominator: Indication: Routine 2019 60,204
TX_PVLS_den Denominator: Indication: Targeted 2019 242
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 251
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 265
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 5,673
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 2,521
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 8,715
TX_RET Numerator by Status: Breastfeeding 2019 46
TX_RET Numerator by Status: Pregnant 2019 619
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 9,678
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 277
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 302
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 6,292
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 2,810
TX_RET_den Denominator by Status: Breastfeeding 2019 51
TX_RET_den Denominator by Status: Pregnant 2019 687
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 61,621
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 1,666
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 1,561
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 41,819
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 16,585
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 49,296
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 49,296
TX_TB_den Life-long ART, Already, TB Screen - Negative, Positive 2019 25,360
TX_TB_den Life-long ART, Already, TB Screen - Positive, Positive 2019 14,328
TX_TB_den Life-long ART, New, TB Screen - Negative, Positive 2019 16,909
TX_TB_den Life-long ART, New, TB Screen - Positive, Positive 2019 5,032
Cross Cutting Budget Categories and Known Amounts Total: $476,464
Gender: Gender Based Violence (GBV) $50,504
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Gender: Gender Equality $14,479
Equity in HIV prevention, care, treatment and support
Monitoring and Evaluation
Capacity building
Implementation
Collection and Use of Gender-related Strategic Information
Economic Strengthening $25,383
Water $18,099
Human Resources for Health $349,900
Food and Nutrition: Commodities $18,099